

DICON Weekly Digest: 1/25/2021

Prepared by: Esther Baker, MSN, RN, CIC, Linda Crane, BSMT (ASCP) SM, CIC, Lynn Cromer, MPH, RN, MT, CPH, CIC, Polly Padgett, BSN, RN, CIC, FAPIC, Kathy Crawford, BSBA-HCM, RN, CIC, Linda Roach, BSMT, CCHM, CIC, Brittain Wood, BSN, RN, CRCST, CIC

COVID-19 Tracker & Statistics:

Duke University Dashboard (updated weekly) [here](#).

UNC Health Dashboard (updated daily) [here](#).

NC DPH Dashboard (updated daily) [here](#).

SC DPH Dashboard (updated daily) [here](#).

GA DPH Dashboard (updated weekly) [here](#).

VA DPH Dashboard (updated daily) [here](#).

WV DPH Dashboard (updated daily) [here](#).

FL DPH Dashboard (updated daily) [here](#).

Johns Hopkins Global Dashboard (updated daily) [here](#).

COVID-19 Guidance & Resources:

DICON website [here](#).

CDC website [here](#).

COVID-19 Vaccine Tracker:

NYT Vaccine Tracker [here](#).

CDC:

- [Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States](#) updated January 21, 2021:
 - Guidance that Pfizer doses can be separated by up to 6 weeks if needed (but 21 days still optimal interval)
 - Guidance that if the manufacturer of the first dose cannot be determined or a dose from the same manufacturer cannot be obtained, administer any mRNA vaccine for 2nd dose 28 days after first dose
 - Updated information on people with dermal fillers
 - Additional resources on excipients
- [MMWR Weekly Update](#) (January 22) highlighted articles:
 - [Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine](#)
 - [COVID-19 Case Investigation and Contact Tracing Efforts from Health Departments](#)
 - [Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites](#)
 - [Emergence of SARS-CoV-2 B.1.1.7 Lineage](#)
 - [COVID-19 Trends Among Persons Aged 0–24 Years](#)
- [Infection Prevention and Control Assessment Tool for Nursing Homes Preparing for COVID-19](#)
- [COVID-19 Vaccination Toolkits](#)

Regulatory Updates:

- The Biden Administration has released the January 2021 [National Strategy for the COVID-19 Response and Pandemic Preparedness](#)

Duke Global Health Institute:

- Scientific Leadership in a Public Health Crisis: A Conversation with Dr. Anthony Fauci and David M. Rubenstein
- Dr. Fauci will join David M. Rubenstein, former chairman of the Duke University Board of Trustees, for a conversation about the pandemic, the U.S. and global response to COVID-19, and his work serving under six presidents to advance public health.
 - Wednesday February 10, 2021 from 4:30pm until 5:15pm
 - Streaming via YouTube Live (no registration required)
 - The link to watch is available [here](#)

Interesting Literature:

- [Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2](#)
- [Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19](#)
- [COVID-19 Testing and Cases in Immigration Detention Centers](#)
- [Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture](#)
- [Evaluation of SARS-CoV-2 transmission mitigation strategies on a university campus using an agent-based network model](#)
- [Population-based Estimates of COVID-19-like Illness, COVID-19 Illness, and Rates of Case Ascertainment, Hospitalizations, and Deaths](#)
- [Airborne Transmission of SARS-CoV-2: What We Know](#)
- [Reopening Schools and the Dynamics of SARS-CoV-2 Infections in Israel: A Nationwide Study](#)
- [The COVID-19 Symptom to Isolation Cascade in A Latinx Community: A Call to Action](#)
- [Effective containment of a COVID-19 sub-regional outbreak in Italy, through strict quarantine and rearrangement of local healthcare services](#)
- [Pre-Procedural SARS-CoV-2 Testing to Sustain Medically-Needed Healthcare Delivery During the COVID-19 Pandemic: A Prospective, Observational Study](#)
- [Opportunistic Fungal Infection Associated with COVID-19](#)
- [Prevalence and Longevity of SARS-CoV-2 Antibodies Among Healthcare Workers](#)

Do you have a suggestion for a new FAQ, position statement, or newsletter?

Reach out [here](#) or discuss with your DICON IP liaison.